WCN26-4224 EFFECT OF FINERENONE ON URINARY ALBUMIN IN PATIENTS WITH T2D AND CKD BY BACKGROUND MEDICATION STATUS: INSIGHTS FROM A RANDOMIZED PLACEBO-CONTROLLED FIVE-STAR STUDY

Read full text Summarise with VIRAT
Authors: Atsushi Tanaka, Takumi Imai, Muthiah Vaduganathan, Masaomi Nangaku, Hirotaka Shibata, Koichi Node
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Finerenone is a selective non-steroidal mineralocorticoid receptor antagonist which reduces urinary albumin, and is beneficial in improving kidney outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). Use of finerenone treatment in patients administered contemporary medications for T2D and CKD is still increasing. However, data on the effect of finerenone on urinary albumin when administered along with background medications such as renin-angiotensin system inhibitors (RASi: angiotensin-converting enzyme inhibitors or angiotensin receptor blockers), sodium-glucose cotransporter-2 inhibitors (SGLT2i), and glucagon-like peptide-1 receptor agonists (GLP-1RA) are limited.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Hormonal Regulation and Hypertension Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104619–104619
Publication date
25 March 2026
Language
EN